198 related articles for article (PubMed ID: 36949068)
1. IGFBP5 is an ROR1 ligand promoting glioblastoma invasion via ROR1/HER2-CREB signaling axis.
Lin W; Niu R; Park SM; Zou Y; Kim SS; Xia X; Xing S; Yang Q; Sun X; Yuan Z; Zhou S; Zhang D; Kwon HJ; Park S; Il Kim C; Koo H; Liu Y; Wu H; Zheng M; Yoo H; Shi B; Park JB; Yin J
Nat Commun; 2023 Mar; 14(1):1578. PubMed ID: 36949068
[TBL] [Abstract][Full Text] [Related]
2. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
3. Ror1 is expressed inducibly by Notch and hypoxia signaling and regulates stem cell-like property of glioblastoma cells.
Ishikawa T; Ogura Y; Tanaka K; Nagashima H; Sasayama T; Endo M; Minami Y
Cancer Sci; 2023 Feb; 114(2):561-573. PubMed ID: 36314076
[TBL] [Abstract][Full Text] [Related]
4. The MAP3K1/c-JUN signaling axis regulates glioblastoma stem cell invasion and tumor progression.
Zhou S; Niu R; Sun H; Kim SH; Jin X; Yin J
Biochem Biophys Res Commun; 2022 Jul; 612():188-195. PubMed ID: 35567901
[TBL] [Abstract][Full Text] [Related]
5. Targeting PDGFRα-activated glioblastoma through specific inhibition of SHP-2-mediated signaling.
Sang Y; Hou Y; Cheng R; Zheng L; Alvarez AA; Hu B; Cheng SY; Zhang W; Li Y; Feng H
Neuro Oncol; 2019 Nov; 21(11):1423-1435. PubMed ID: 31232447
[TBL] [Abstract][Full Text] [Related]
6. IGFBP5 increases cell invasion and inhibits cell proliferation by EMT and Akt signaling pathway in Glioblastoma multiforme cells.
Dong C; Zhang J; Fang S; Liu F
Cell Div; 2020; 15():4. PubMed ID: 32127912
[TBL] [Abstract][Full Text] [Related]
7. Targeting ROR1 inhibits the self-renewal and invasive ability of glioblastoma stem cells.
Jung EH; Lee HN; Han GY; Kim MJ; Kim CW
Cell Biochem Funct; 2016 Apr; 34(3):149-57. PubMed ID: 26923195
[TBL] [Abstract][Full Text] [Related]
8. REST-DRD2 mechanism impacts glioblastoma stem cell-mediated tumorigenesis.
Marisetty AL; Lu L; Veo BL; Liu B; Coarfa C; Kamal MM; Kassem DH; Irshad K; Lu Y; Gumin J; Henry V; Paulucci-Holthauzen A; Rao G; Baladandayuthapani V; Lang FF; Fuller GN; Majumder S
Neuro Oncol; 2019 Jun; 21(6):775-785. PubMed ID: 30953587
[TBL] [Abstract][Full Text] [Related]
9. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059
[TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.
Zhou W; Cheng L; Shi Y; Ke SQ; Huang Z; Fang X; Chu CW; Xie Q; Bian XW; Rich JN; Bao S
Oncotarget; 2015 Nov; 6(35):37300-15. PubMed ID: 26510911
[TBL] [Abstract][Full Text] [Related]
11. JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma.
Zheng Q; Han L; Dong Y; Tian J; Huang W; Liu Z; Jia X; Jiang T; Zhang J; Li X; Kang C; Ren H
Neuro Oncol; 2014 Sep; 16(9):1229-43. PubMed ID: 24861878
[TBL] [Abstract][Full Text] [Related]
12. The dopamine receptor D1 inhibitor, SKF83566, suppresses GBM stemness and invasion through the DRD1-c-Myc-UHRF1 interactions.
Xue Z; Zhang Y; Zhao R; Liu X; Grützmann K; Klink B; Zhang X; Wang S; Zhao W; Sun Y; Han M; Wang X; Hu Y; Liu X; Yang N; Qiu C; Li W; Huang B; Li X; Bjerkvig R; Wang J; Zhou W
J Exp Clin Cancer Res; 2024 Jan; 43(1):25. PubMed ID: 38246990
[TBL] [Abstract][Full Text] [Related]
13. Targeting of glioma stem-like cells with a parthenolide derivative ACT001 through inhibition of AEBP1/PI3K/AKT signaling.
Hou Y; Sun B; Liu W; Yu B; Shi Q; Luo F; Bai Y; Feng H
Theranostics; 2021; 11(2):555-566. PubMed ID: 33391492
[TBL] [Abstract][Full Text] [Related]
14. miR-27b-3p suppresses cell proliferation through targeting receptor tyrosine kinase like orphan receptor 1 in gastric cancer.
Tao J; Zhi X; Zhang X; Fu M; Huang H; Fan Y; Guan W; Zou C
J Exp Clin Cancer Res; 2015 Nov; 34():139. PubMed ID: 26576539
[TBL] [Abstract][Full Text] [Related]
15. Sulforaphane suppresses the growth of glioblastoma cells, glioblastoma stem cell-like spheroids, and tumor xenografts through multiple cell signaling pathways.
Bijangi-Vishehsaraei K; Reza Saadatzadeh M; Wang H; Nguyen A; Kamocka MM; Cai W; Cohen-Gadol AA; Halum SL; Sarkaria JN; Pollok KE; Safa AR
J Neurosurg; 2017 Dec; 127(6):1219-1230. PubMed ID: 28059653
[TBL] [Abstract][Full Text] [Related]
16. Engagement of cellular prion protein with the co-chaperone Hsp70/90 organizing protein regulates the proliferation of glioblastoma stem-like cells.
Iglesia RP; Prado MB; Cruz L; Martins VR; Santos TG; Lopes MH
Stem Cell Res Ther; 2017 Apr; 8(1):76. PubMed ID: 28412969
[TBL] [Abstract][Full Text] [Related]
17. A curcumin derivative hydrazinobenzoylcurcumin suppresses stem-like features of glioblastoma cells by targeting Ca
Shin HJ; Lee S; Jung HJ
J Cell Biochem; 2019 Apr; 120(4):6741-6752. PubMed ID: 30390339
[TBL] [Abstract][Full Text] [Related]
18. Elevated invasive potential of glioblastoma stem cells.
Cheng L; Wu Q; Guryanova OA; Huang Z; Huang Q; Rich JN; Bao S
Biochem Biophys Res Commun; 2011 Mar; 406(4):643-8. PubMed ID: 21371437
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
[TBL] [Abstract][Full Text] [Related]
20. NFAT1-Mediated Regulation of NDEL1 Promotes Growth and Invasion of Glioma Stem-like Cells.
Jiang Y; Song Y; Wang R; Hu T; Zhang D; Wang Z; Tie X; Wang M; Han S
Cancer Res; 2019 May; 79(10):2593-2603. PubMed ID: 30940662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
